| DILI | Drug-Induced Liver Injury |
| GWAs | Genome-wide association study |
| HDS | Herbal and Diet Supplements |
| ALF | Acute liver failure |
| DILIN | Drug Induced Liver Injury Network |
| ALT | Alanin-aminotransferase |
| ULN | Upper limit of normal |
| ALP | Alkaline Phosphatase |
| TB | Total Bilirrubin |
| AST | Aspartate-aminotransferase |
| OLT | Orthotopic liver transplantation |
| GGT | G-glutamyl transpeptidase |
| AIH | Autoimmune hepatitis |
| RUCAM | Roussel Uclaf Causality Assessment Method |
| CTLA-4 | Cytotoxic-T lymphocyte A-4 |
| PD-1 | Programed death-1 |
| SOS | Sinusoidal obstruction syndrome |
| HLA | Human Leukocyte Antigen |
| DAMPS | Damage Associated Molecular Patterns |
| FDA | Food and Drug Administration |
| ROS | Reactive oxygen species |
| mtDNA | Mitochondrial deoxyribonucleic acid |
| BSEP | Bile salt export pump |
| MRP | Multidrug resistance-associated protein |
| HIV | Human immunodeficiency virus |
| HBV | Hepatitis B virus |
| HCV | Hepatitis C virus |
| NAFLD | Non-alcoholic fatty liver disease |
| CYP | Cytochrome |
| GPRD | General Practice Research Database |